Abstract 2715: Treatment of disseminated HER-2 carcinomas with a HER-2-retargeted oncolytic herpes virus

Oncolytic viruses hold the promise to spare normal cells and to selectively seek and destroy tumor cells within the body. Until now numerous viruses where successfully engineered to confer or enhance tumor selectivity, however the effective targeting of disseminated tumor cells in vivo remains a major hurdle. We have retargeted herpes simpex virus (HSV) through the replacement of key gD sequences with sequences encoding a HER-2-specific single...